Gadolinium-DTPA enhancement of an optic nerve and chiasmal meningioma.
The advent of gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA), a magnetic resonance imaging (MRI) contrast agent, has significantly improved MRI's diagnostic accuracy by enabling the physician to separate magnetically similar but histologically different tissues. A patient with optic nerve meningioma, whose tumor was clearly demonstrated on Gd-DTPA-enhanced MRI but did not appear on noncontrast MRI, is described. The usefulness of contrast agents in MRI diagnosis of neuro-ophthalmologic disorders and ophthalmic tumors is emphasized through this case report.
Haik
B G
BG
Department of Ophthalmology, Tulane University School of Medicine, New Orleans, Louisiana 70112-2699.
Zimmerman
R
R
Saint Louis
L
L
D000368:Aged; D003390:Cranial Nerve Neoplasms / Q000175:diagnosis*; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008579:Meningioma / Q000175:diagnosis*; D009901:Optic Nerve Diseases / Q000175:diagnosis*; D009942:Organometallic Compounds; D004369:Pentetic Acid; D014057:Tomography, X-Ray Computed; D014792:Visual Acuity
D009942:Organometallic Compounds; D004369:Pentetic Acid; D019786:Gadolinium DTPA